211 related articles for article (PubMed ID: 28396999)
1. Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations.
Moreira DM; Andriole GL; Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ
World J Urol; 2017 Oct; 35(10):1525-1530. PubMed ID: 28396999
[TBL] [Abstract][Full Text] [Related]
2. Effect of dutasteride on the risk of prostate cancer.
Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
[TBL] [Abstract][Full Text] [Related]
3. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
[TBL] [Abstract][Full Text] [Related]
4. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
[TBL] [Abstract][Full Text] [Related]
5. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Moreira DM; Bostwick DG; Andriole GL; Peterson BL; Cohen HJ; Castro-Santamaria R; Freedland SJ
J Urol; 2015 Nov; 194(5):1241-6. PubMed ID: 26165588
[TBL] [Abstract][Full Text] [Related]
6. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
7. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
11. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
[TBL] [Abstract][Full Text] [Related]
12. Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal A; Castro-Santamaria R; Freedland SJ
J Urol; 2017 Sep; 198(3):650-656. PubMed ID: 28428110
[TBL] [Abstract][Full Text] [Related]
13. Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Allott EH; Csizmadi I; Howard LE; Muller RL; Moreira DM; Andriole GL; Roehrborn CG; Freedland SJ
BJU Int; 2020 Feb; 125(2):226-233. PubMed ID: 31479563
[TBL] [Abstract][Full Text] [Related]
14. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
Kramer JJ; Gu L; Moreira D; Andriole G; Csizmadi I; Freedland SJ
J Urol; 2022 Feb; 207(2):417-423. PubMed ID: 34544265
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
[TBL] [Abstract][Full Text] [Related]
16. The Association of Previous Prostate Biopsy Related Complications and the Type of Complication with Patient Compliance with Rebiopsy Scheme.
Schwarzman LS; Abern MR; Garvey DF; Andriole GL; Freedland SJ; Moreira DM
J Urol; 2018 Nov; 200(5):1062-1067. PubMed ID: 29906435
[TBL] [Abstract][Full Text] [Related]
17. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.
Moreira DM; Nickel JC; Gerber L; Muller RL; Andriole GL; Castro-Santamaria R; Freedland SJ
Cancer; 2014 Jan; 120(2):190-6. PubMed ID: 24323568
[TBL] [Abstract][Full Text] [Related]
18. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
19. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
Fleshner NE; Lucia MS; Egerdie B; Aaron L; Eure G; Nandy I; Black L; Rittmaster RS
Lancet; 2012 Mar; 379(9821):1103-11. PubMed ID: 22277570
[TBL] [Abstract][Full Text] [Related]
20. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
